Obesity Week 2026 | Laekna Announces Poster Presentation on LAE124, an Internally Discovered Oral Small-Molecule Amylin Receptor Agonist

Detailed summary

SHANGHAI, Nov. 11, 2026 /PRNewswire/ -- Laekna (2105.HK) announced that LAE124, its internally discovered novel oral small-molecule dual Amylin/Calcitonin receptor agonist (DACRA)…

SHANGHAI, Nov. 11, 2026 /PRNewswire/ -- Laekna (2105.HK) announced that LAE124, its internally discovered novel oral small-molecule dual Amylin/Calcitonin receptor agonist (DACRA) for the treatment of obesity, has been selected for a poster presentation at the 44th Annual Meeting of The Obesity Society, to be held in conjunction with Obesity Week 2026. The research will be presented in the "Emerging Weight-Loss Therapies & Long-Term Outcomes" session on November 15. Obesity Week 2026, one of the premier international conferences in the obesity field, will take place from November 14 to 17 in Washington, D.C., USA.

LAE124 is currently in IND-enabling studies. Dr. Justin GU, Chief Scientific Officer of Laekna, said: "Amylin analogs, which act through a novel mechanism in weight management, have demonstrated robust weight-loss efficacy in obese patients. The combination of Amylin analogs with GLP-1 analogs could lead to further weight loss. However, most of the Amylin analogs currently in clinical development are peptide drugs and require subcutaneous administration. Orally available small molecule DACRA will be highly competitive in the obesity market due to improved dosing convenience and enhanced patient adherence."

Data showed that LAE124, discovered internally by Laekna, demonstrated excellent pharmacological efficacy in animal studies:

Dr. Gu stated that the development of LAE124 further underscores Laekna's extensive experience and deep scientific foundation in metabolic diseases and its increasingly diversified innovative pipeline. In addition to the multiple drug candidates of targeting the ActRII receptor (LAE102, LAE103 and LAE123), Laekna is also accelerating the development of therapies targeting novel pathways such as Amylin and UCN2, building a portfolio of metabolic disease and obesity therapies driven by new mechanisms of action.

Poster Title: LAE124: A Novel Oral Small Molecule Dual Amylin/Calcitonin Receptor Agonist for Treatment of Obesity

Location…

The…

P…

Opening of the article, excerpted from PR Newswire. To read the rest, open the article on the publisher's site.